BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zedoresertib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zedoresertib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06612203-9091@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Zedoresertib: Phase 1/2 readout est. (NCT06612203)
DESCRIPTION:Zedoresertib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combi
 nation in TNBC or HR+/HER2- Advanced Breast Cancer\nEstimated primary comp
 letion: February 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/zedoresertib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06612203
URL:https://assetmemo.bio/drug/zedoresertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04855656-9091@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zedoresertib: Phase 1 readout est. (NCT04855656)
DESCRIPTION:Zedoresertib\, phase 1.\nStudy: Study of Lunresertib Alone or i
 n Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With A
 dvanced Solid Tumors\nEstimated primary completion: December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/zedoresertib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04855656
URL:https://assetmemo.bio/drug/zedoresertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05765812-9091@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Zedoresertib: Phase 1/2 readout est. (NCT05765812)
DESCRIPTION:Zedoresertib\, phase 1/2\, Glioblastoma.\nStudy: A Study of Zed
 oresertib (Debio 0123) in Combination With Temozolomide in Adult Participa
 nts With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 
 0123) in Combination With Temozolomide and Radiotherapy in Adult Participa
 nts With Newly Diagnosed Glioblastoma\nEstimated primary completion: Septe
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zedoresert
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5765812
URL:https://assetmemo.bio/drug/zedoresertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
